


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~Compounds~~ A compound of the formula I



in which

D denotes aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms which is unsubstituted or mono- or polysubstituted by Hal, A, OR², N(R²)₂, NO₂, CN, COOR² or CON(R²)₂,

X denotes -C=O or C(R³)₂,

W denotes -[C(R³)₂]_n-,

R¹ denotes H or A, which may be substituted by OR³, S(O)_nR³, N(R³)₂, CN, COOR³, CON(R³)₂, OCON(R³)₂, N(R³)COOR³, N(R³)CON(R³)₂, N(R³)SO₂R³, SO₂N(R³)₂ or -C≡C-,

R² denotes H, A, -[C(R³)₂]_n-Ar', -[C(R³)₂]_n-Het', -[C(R³)₂]_n-cycloalkyl, -[C(R³)₂]_n-N(R³)₂ or -[C(R³)₂]_n-OR³,

R³ denotes H or A,

Y denotes alkylene, cycloalkylene, Het-diyl or Ar-diyl,

T denotes a mono- or bicyclic saturated, unsaturated or aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms which is mono- or disubstituted by =O, =S, =NR², =N-CN, =N-NO₂, =NOR², =NCOR², =NCOOR², and/or =NOCOR² and may furthermore be mono-, di- or trisubstituted by R², Hal, A, -[C(R³)₂]_n-Ar, -[C(R³)₂]_n-Het, -[C(R³)₂]_n-cycloalkyl, OR², N(R²)₂, NO₂, CN, COOR², CON(R²)₂, NR²COA, NR²CON(R²)₂, NR²SO₂A, COR², SO₂NR² and/or S(O)_nA,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two CH₂ groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or also 1-7 H atoms may be replaced by F,

Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR², N(R²)₂, NO₂, CN, COOR², CON(R²)₂, NR²COA,

$\text{NR}^2\text{CON}(\text{R}^2)_2$, $\text{NR}^2\text{SO}_2\text{A}$, COR^2 , $\text{SO}_2\text{N}(\text{R}^2)_2$, $\text{S}(\text{O})_n\text{A}$, $-\text{C}(\text{R}^3)_2]_n\text{-COOR}^2$ or $-\text{O}-\text{C}(\text{R}^3)_2]_o\text{-COOR}^2$,

Ar' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^3 , $\text{N}(\text{R}^3)_2$, NO_2 , CN, COOR^3 , $\text{CON}(\text{R}^3)_2$, NR^3COA , $\text{NR}^3\text{CON}(\text{R}^3)_2$, $\text{NR}^3\text{SO}_2\text{A}$, COR^3 , $\text{SO}_2\text{N}(\text{R}^3)_2$, $\text{S}(\text{O})_n\text{A}$, $-\text{C}(\text{R}^3)_2]_n\text{-COOR}^3$ or $-\text{O}-\text{C}(\text{R}^3)_2]_o\text{-COOR}^3$,

Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen, =S, =N(R^2)₂, Hal, A, $-\text{C}(\text{R}^3)_2]_n\text{-Ar}$, $-\text{C}(\text{R}^3)_2]_n\text{-Het}'$, $-\text{C}(\text{R}^3)_2]_n\text{-cycloalkyl}$, $-\text{C}(\text{R}^3)_2]_n\text{-OR}^2$, $-\text{C}(\text{R}^3)_2]_n\text{-N}(\text{R}^3)_2$, NO_2 , CN, $-\text{C}(\text{R}^3)_2]_n\text{-COOR}^{2'}$, $-\text{C}(\text{R}^3)_2]_n\text{-CON}(\text{R}^2)_2$, $-\text{C}(\text{R}^3)_2]_n\text{-NR}^2\text{COA}$, $\text{NR}^2\text{CON}(\text{R}^2)_2$, $-\text{C}(\text{R}^3)_2]_n\text{-NR}^2\text{SO}_2\text{A}$, COR^2 , SO_2NR^2 and/or $\text{S}(\text{O})_n\text{A}$,

Het' denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by carbonyl oxygen, =S, =N(R^3)₂, Hal, A, OR^3 , $\text{N}(\text{R}^3)_2$, NO_2 , CN, COOR^3 , $\text{CON}(\text{R}^3)_2$, NR^3COA , $\text{NR}^3\text{CON}(\text{R}^3)_2$, $\text{NR}^3\text{SO}_2\text{A}$, COR^3 , SO_2NR^3 and/or $\text{S}(\text{O})_n\text{A}$,

Hal denotes F, Cl, Br or I,

m denotes 1 or 2,

n denotes 0, 1 or 2, and

o denotes 1, 2 or 3,

and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

2. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, in which

D denotes an aromatic five-ring heterocycle having 1 to 2 N, O and/or S atoms which is unsubstituted or mono- or disubstituted by Hal,

and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

3. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, in which

D denotes a thienyl ring which is mono- or disubstituted by Hal,
and ~~or a pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~
~~including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer
thereof, or a mixture thereof.

4. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in
which

R² denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,
and ~~or a pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~
~~including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer
thereof, or a mixture thereof.

5. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in
which

R¹ denotes H or A, which may be substituted by OR³, CON(R³)₂, N(R³)₂,
S(O)_nR³, COOR³, OCON(R³)₂, N(R³)COOR³ or -C≡C-,
and ~~or a pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~
~~including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer
thereof, or a mixture thereof.

6. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in
which

X denotes -C=O,
and ~~or a pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~
~~including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer
thereof, or a mixture thereof.

7. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in
which

W is absent,
and ~~or a pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~
~~including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer
thereof, or a mixture thereof.

8. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in which

Y denotes Ar-diyl,

~~and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

9. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in which

T denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N and/or O atoms which is mono- or disubstituted by =O, =S, =NR², =N-CN, =N-NO₂, =NOR², =NCOR², =NCOOR² or =NOCOR² and may furthermore be mono- or disubstituted by Hal or A,

~~and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

10. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in which

T denotes a mono- or bicyclic saturated or unsaturated heterocycle having 1 to 2 N and/or O atoms which is mono- or disubstituted by =O, =S or =NH,

~~and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

11. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in which

T denotes piperidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo[2.2.2]-octan-2-yl, each of which is mono- or disubstituted by =O or =NH,

and ~~or a pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~
~~including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer
thereof, or a mixture thereof.

12. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in
which

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by Hal, A,
OA, SO₂A, COOR², SO₂NH₂ or CN,

~~and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~
~~including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer
thereof, or a mixture thereof.

13. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in
which

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by A and/or
Hal,

~~and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~
~~including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer
thereof, or a mixture thereof.

14. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in
which

D denotes aromatic five-ring heterocycle having 1 to 2 N, O and/or S atoms
which is unsubstituted or mono- or disubstituted by Hal,

R¹ denotes H or A, which may be substituted by OR³, CON(R³)₂, N(R³)₂,
S(O)_nR³, COOR³, OCON(R³)₂, N(R³)COOR³ or -C≡C-,

R² denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

X denotes -C=O or CH₂,

W is absent,

Y denotes Ar-diyl,

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by A and/or
Hal, and

T denotes a mono- or bicyclic saturated or unsaturated heterocycle having 1 to 2 N and/or O atoms which is mono- or disubstituted by =O, =S or =NH,

~~and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

15. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in which

D denotes thienyl, thiazolyl or furyl, each of which is mono- or disubstituted by Hal,

R¹ denotes H or A, which may be substituted by OR³, CON(R³)₂, N(R³)₂, S(O)_nR³, COOR³, OCON(R³)₂, N(R³)COOR³ or -C≡C-,

R² denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

X denotes -C=O or CH₂,

W is absent,

Y denotes Ar-diyl,

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by A and/or Hal, and

T denotes piperidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo-[2.2.2]octan-2-yl, each of which is mono- or disubstituted by =O or =NH,

~~and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

16. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in which

D denotes thienyl or phenyl, each of which is mono- or disubstituted by Hal,

R¹ denotes H or A, which may be substituted by OR³, CON(R³)₂, N(R³)₂, S(O)_nR³, COOR³, OCON(R³)₂, N(R³)COOR³ or -C≡C-,

R² denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

R³ denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

X denotes -C=O or CH₂,

W is absent or denotes CH₂,
Y denotes Ar-diyl,
A denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, in which one or two CH₂ groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or also 1-7 H atoms may be replaced by F,

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by A and/or Hal, and

T denotes piperidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo-[2.2.2]octan-2-yl, each of which is mono- or disubstituted by =O or =NH,

and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

17. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~selected from the group which is~~

(S)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(S)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(S)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-iminopiperidin-1-yl)phenyl]-4-methylvaleramide,

(S)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-iminopiperidin-1-yl)phenyl]-4-

methylvaleramide,

2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(2-oxopiperidin-1-yl)phenyl]acetamide,

3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(2-oxopiperidin-1-yl)phenyl]propionamide,

(*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]propionamide,

(*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-methylbutyramide,

(*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]butyramide,

(*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]valeramide,

(*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-aminocarbonylpropionamide,

(*R*)-2-[(4-chlorophenylcarbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(*R*)-2-[(4-chlorophenylcarbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(*N,N*-dimethylamino)propionamide,

(*R*)-2-[(5-bromothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxopiperidin-1-yl)benzyl]-4-methylvaleramide,

2-[(5-chlorothiophene-2-methyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-methylsulfanylpropionamide,

(*S*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxopiperidin-1-yl)benzyl]-4-methylvaleramide,

(*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-methylbutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methylbutyramide,

3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]propionamide,

3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]propionamide,

3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]propionamide,

2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]acetamide,

2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]acetamide,

3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-2-butylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]valeramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methylsulfanylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyrazin-1-yl)-phenyl]propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylsulfanylbutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-ethynylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-ethynylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-fluoro-4-(3-oxomorpholin-4-yl)-phenyl]propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-4-methylsulfanylbutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-(*tert*-butyloxycarbonyl)propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-vinylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-vinylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-(*tert*-butyloxycarbonyl)propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methoxybutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-methoxybutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]valeramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-(*tert*-butyloxycarbonyl)butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-(*tert*-butyloxycarbonyl)butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxopiperidin-1-yl)phenyl]-4-(*tert*-butyloxycarbonyl)butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-(*tert*-butyloxycarbonylamino)butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-4-(*tert*-butyloxycarbonylamino)butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-5-(*tert*-butoxycarbonylamino)valeramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-5-(*tert*-butoxycarbonylamino)valeramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-(*tert*-butoxycarbonylamino)propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-(*tert*-butoxycarbonylamino)propionamide,

(R)-3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]butyramide,

(R)-3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-5-methyladipamide,

(S)-3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-5-methyladipamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-methoxypropionamide,

(2*R*,3*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxo-morpholin-4-yl)-phenyl]-3-methoxybutyramide,

(2*R*,3*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-methoxybutyramide,

(S)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-trifluoromethyl-4-(3-oxomorpholin-4-yl)phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-chloro-4-(2-azabicyclo[2.2.2]octan-2-yl)phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-trifluoromethoxy-4-(2-azabicyclo[2.2.2]octan-2-yl)phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-chloro-4-(3-oxomorpholin-4-yl)-phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-fluoro-4-(3-oxomorpholin-4-yl)-phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-chloro-4-(2-oxo-2*H*-pyridin-1-yl)-phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-allylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-propoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-ethoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-(2-methoxyethoxy)propionamide,

(2*R*,3*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-ethoxybutyramide,

(2*R*,3*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(2-methoxyethoxy)butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-methylsulfonylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methylsulfonylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-methylsulfonylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-methylsulfonylbutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-methylsulfonylbutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methylsulfonylbutyramide,

(R)-2-[(5-chlorothiophen-2-ylmethyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]valeramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-carboxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-carboxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-carboxybutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-4-carboxybutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-aminobutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-4-aminobutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-5-aminovaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-5-aminovaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-aminopropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-aminopropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-hydroxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-4-(3-oxomorpholin-4-yl)phenyl]-3-hydroxypropionamide,

(2R,3R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-hydroxybutyramide,

(2R,3R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-aminocarbonyloxybutyramide,

(2R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-aminocarbonyloxypropionamide, or

(2R,3R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-aminocarbonyloxybutyramide,

~~and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~
~~including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

18. (Withdrawn and Currently Amended) ~~Process A process for the preparation of compounds of the~~ preparing a compound of formula I according to claim 1 and or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, characterised in that acceptable salt, hydrate, alcoholate or stereoisomer thereof, comprising


a) reacting a compound of the formula II



in which

W, Y and T have the meanings indicated ~~in Claim 1~~ for the compound of formula I,

~~is reacted~~ with a compound of the formula III



in which


L denotes Cl, Br, I or a free or reactively functionally modified OH group, and

R¹, m, X and D have the meanings indicated ~~in Claim 1~~ for the compound of formula I,

or


b) for the preparation of compounds of the a compound of formula I,
in which X denotes -C=O,

reacting a compound of the formula IV



in which R^1 , m, W, Y and T have the meanings indicated ~~in Claim 1~~ for the compound of formula I,

~~is reacted~~ with a compound of the formula V



in which


L denotes Cl, Br, I or a free or reactively functionally modified OH group, and

D has the meaning indicated ~~in Claim 1~~ for the compound of formula I,

or

c) ~~for the preparation of compounds of the~~ a compound of formula I
in which X denotes CH_2 ,

reacting a compound of the formula IV



in which R^1 , m, W, Y and T have the meanings indicated ~~in Claim 1~~ for the compound of formula I,

~~is reacted~~ with a compound of the formula VI



in which

D has the meaning indicated ~~in Claim 1~~ for the compound of formula I,
in a reductive amination,

and/or

a base or acid of the compound of formula I is converted into one of its salts, hydrates or alcoholates.

19. (Currently Amended) ~~Compounds of the formula I according to claim 1 as inhibitors of~~ A method for inhibiting coagulation factor Xa, comprising administering a compound of formula I according to claim 1 in an effective amount to inhibit coagulation factor Xa.

20. (Currently Amended) ~~Compounds~~ A compound of the formula I according to claim 1 as inhibitors of coagulation factor VIIa, comprising administering a compound of formula I according to claim 1 in an effective amount to inhibit coagulation factor VIIa.

21. (Currently Amended) ~~Medicaments comprising at least one~~ A pharmaceutical composition comprising a compound of the formula I according to claim 1 and/or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof, and a pharmaceutically acceptable excipient and/or adjuvant.

22. (Currently Amended) ~~Medicaments comprising at least one compound of the formula I according to claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament~~ A pharmaceutical composition according to claim 21, further comprising a pharmaceutically active ingredient other than the compound of formula I.

23. (Withdrawn and Currently Amended) ~~Use of compounds according to claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of~~ A method for treating thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases a tumor, a tumor disease and/or tumor metastases, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 21.


24. (Currently Amended) ~~Set (kit) consisting of~~ A set or kit comprising separate packs of

(a) ~~an effective amount of a compound of the formula I according to claim 1 and/or a pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof,

and

(b) ~~an effective amount of a further medicament~~ a pharmaceutically active ingredient other than the compound of formula I.

25. (New) A compound of formula I



in which

D denotes aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms which is unsubstituted or mono- or polysubstituted by Hal, A, OR², N(R²)₂, NO₂, CN, COOR² or CON(R²)₂,

X denotes -C=O or C(R³)₂,

W denotes -[C(R³)₂]_n-,

R¹ denotes H or A, which may be substituted by OR³, S(O)_nR³, N(R³)₂, CN, COOR³, CON(R³)₂, OCON(R³)₂, N(R³)COOR³, N(R³)CON(R³)₂, N(R³)SO₂R³, SO₂N(R³)₂ or -C≡C-,

R² denotes H, A, -[C(R³)₂]_n-Ar', -[C(R³)₂]_n-Het', -[C(R³)₂]_n-cycloalkyl, -[C(R³)₂]_n-N(R³)₂ or -[C(R³)₂]_n-OR³,

R³ denotes H or A,

Y denotes alkylene, cycloalkylene, Het-diyl or Ar-diyl,

T denotes a mono- or bicyclic saturated, unsaturated or aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms which is mono- or disubstituted by =O, =S, =NR², =N-CN, =N-NO₂, =NOR², =NCOR², =NCOOR², and/or =NOCOR² and may furthermore be mono-, di- or trisubstituted by R², Hal, A, -[C(R³)₂]_n-Ar, -[C(R³)₂]_n-Het, -[C(R³)₂]_n-cycloalkyl, OR², N(R²)₂, NO₂, CN, COOR², CON(R²)₂, NR²COA, NR²CON(R²)₂,

$\text{NR}^2\text{SO}_2\text{A}$, COR^2 , SO_2NR^2 and/or $\text{S(O)}_n\text{A}$,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two CH_2 groups may be replaced by O or S atoms and/or by $-\text{CH}=\text{CH}-$ groups and/or 1-7 H atoms may be replaced by F,

Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^2 , $\text{N(R}^2)_2$, NO_2 , CN, COOR^2 , $\text{CON(R}^2)_2$, NR^2COA , $\text{NR}^2\text{CON(R}^2)_2$, $\text{NR}^2\text{SO}_2\text{A}$, COR^2 , $\text{SO}_2\text{N(R}^2)_2$, $\text{S(O)}_n\text{A}$, $-\text{[C(R}^3)_2]_n-\text{COOR}^2$ or $-\text{O-[C(R}^3)_2]_o-\text{COOR}^2$,

Ar' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^3 , $\text{N(R}^3)_2$, NO_2 , CN, COOR^3 , $\text{CON(R}^3)_2$, NR^3COA , $\text{NR}^3\text{CON(R}^3)_2$, $\text{NR}^3\text{SO}_2\text{A}$, COR^3 , $\text{SO}_2\text{N(R}^3)_2$, $\text{S(O)}_n\text{A}$, $-\text{[C(R}^3)_2]_n-\text{COOR}^3$ or $-\text{O-[C(R}^3)_2]_o-\text{COOR}^3$,

Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen, $=\text{S}$, $=\text{N(R}^2)_2$, Hal, A, $-\text{[C(R}^3)_2]_n-\text{Ar}$, $-\text{[C(R}^3)_2]_n-\text{Het'}$, $-\text{[C(R}^3)_2]_n-\text{cycloalkyl}$, $-\text{[C(R}^3)_2]_n-\text{OR}^2$, $-\text{[C(R}^3)_2]_n-\text{N(R}^3)_2$, NO_2 , CN, $-\text{[C(R}^3)_2]_n-\text{COOR}^2$, $-\text{[C(R}^3)_2]_n-\text{CON(R}^2)_2$, $-\text{[C(R}^3)_2]_n-\text{NR}^2\text{COA}$, $\text{NR}^2\text{CON(R}^2)_2$, $-\text{[C(R}^3)_2]_n-\text{NR}^2\text{SO}_2\text{A}$, COR^2 , SO_2NR^2 and/or $\text{S(O)}_n\text{A}$,

Het' denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by carbonyl oxygen, $=\text{S}$, $=\text{N(R}^3)_2$, Hal, A, OR^3 , $\text{N(R}^3)_2$, NO_2 , CN, COOR^3 , $\text{CON(R}^3)_2$, NR^3COA , $\text{NR}^3\text{CON(R}^3)_2$, $\text{NR}^3\text{SO}_2\text{A}$, COR^3 , SO_2NR^3 and/or $\text{S(O)}_n\text{A}$,

Hal denotes F, Cl, Br or I,

m denotes 1 or 2,

n denotes 0, 1 or 2, and

o denotes 1, 2 or 3,

or a pharmaceutically acceptable salt thereof.